1. Home
  2. ACET vs ATOM Comparison

ACET vs ATOM Comparison

Compare ACET & ATOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACET
  • ATOM
  • Stock Information
  • Founded
  • ACET 1947
  • ATOM 2001
  • Country
  • ACET United States
  • ATOM United States
  • Employees
  • ACET N/A
  • ATOM N/A
  • Industry
  • ACET Biotechnology: Pharmaceutical Preparations
  • ATOM Semiconductors
  • Sector
  • ACET Health Care
  • ATOM Technology
  • Exchange
  • ACET Nasdaq
  • ATOM Nasdaq
  • Market Cap
  • ACET 93.1M
  • ATOM 100.9M
  • IPO Year
  • ACET N/A
  • ATOM 2016
  • Fundamental
  • Price
  • ACET $0.96
  • ATOM $7.99
  • Analyst Decision
  • ACET Strong Buy
  • ATOM Strong Buy
  • Analyst Count
  • ACET 4
  • ATOM 1
  • Target Price
  • ACET $5.67
  • ATOM $7.00
  • AVG Volume (30 Days)
  • ACET 790.0K
  • ATOM 432.5K
  • Earning Date
  • ACET 11-06-2024
  • ATOM 02-11-2025
  • Dividend Yield
  • ACET N/A
  • ATOM N/A
  • EPS Growth
  • ACET N/A
  • ATOM N/A
  • EPS
  • ACET N/A
  • ATOM N/A
  • Revenue
  • ACET N/A
  • ATOM $662,000.00
  • Revenue This Year
  • ACET N/A
  • ATOM N/A
  • Revenue Next Year
  • ACET N/A
  • ATOM $2,800.00
  • P/E Ratio
  • ACET N/A
  • ATOM N/A
  • Revenue Growth
  • ACET N/A
  • ATOM 13140.00
  • 52 Week Low
  • ACET $0.89
  • ATOM $2.31
  • 52 Week High
  • ACET $3.77
  • ATOM $9.19
  • Technical
  • Relative Strength Index (RSI)
  • ACET 37.36
  • ATOM 71.02
  • Support Level
  • ACET $0.91
  • ATOM $7.04
  • Resistance Level
  • ACET $1.12
  • ATOM $7.99
  • Average True Range (ATR)
  • ACET 0.09
  • ATOM 0.61
  • MACD
  • ACET 0.00
  • ATOM 0.06
  • Stochastic Oscillator
  • ACET 16.21
  • ATOM 95.78

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

About ATOM Atomera Incorporated

Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the most widely used transistor type in the semiconductor industry. The mears silicon technology of the company can be used for applications like Analog, DRAM, FinFET technology, logic and processors, and SRAM.

Share on Social Networks: